Continuous intravenous milrinone for severe reversible cerebral vasoconstriction syndrome (a case report)
- 20 December 2018
- journal article
- letter
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 397, 55-57
Abstract
No abstract availableKeywords
Funding Information
- Aspen, LFB, Baxter and Nordic pharma
This publication has 12 references indexed in Scilit:
- Reversible Cerebral Vasoconstriction Syndrome: Recognition and TreatmentCurrent Treatment Options in Neurology, 2017
- Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndromeNeurology, 2017
- A Novel Approach to Diagnose Reversible Cerebral Vasoconstriction Syndrome: A Case SeriesJournal of Stroke and Cerebrovascular Diseases, 2015
- European Stroke Organization Guidelines for the Management of Intracranial Aneurysms and Subarachnoid HaemorrhageCerebrovascular Diseases, 2013
- Reversible cerebral vasoconstriction syndromeThe Lancet Neurology, 2012
- Milrinone and Homeostasis to Treat Cerebral Vasospasm Associated with Subarachnoid Hemorrhage: The Montreal Neurological Hospital ProtocolNeurocritical Care, 2012
- Critical Care Management of Patients Following Aneurysmal Subarachnoid Hemorrhage: Recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus ConferenceNeurocritical Care, 2011
- Hemodynamic Management and Outcome of Patients Treated for Cerebral Vasospasm with Intraarterial Nicardipine and/or MilrinoneAnesthesia & Analgesia, 2010
- Intra‐Arterial Milrinone for Reversible Cerebral Vasoconstriction SyndromeHeadache: The Journal of Head and Face Pain, 2009
- Milrinone for the Treatment of Cerebral Vasospasm After Aneurysmal Subarachnoid HemorrhageStroke, 2008